Role of Cabozantinib and Nivolumab in Advanced RCC

When added to tivozanib, nivolumab did not lead to improved clinical outcomes in metastatic renal cell carcinoma.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Fianlimab plus cemiplimab was well-tolerated and showed durable responses, in pretreated patients with advanced clear cell renal carcinoma.

In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma.